Header

UZH-Logo

Maintenance Infos

Treatment of infantile haemangiomas: recommendations of a European expert group


Hoeger, Peter H; Harper, John I; Baselga, Eulalia; Bonnet, Damien; Boon, Laurence M; Atti, Marta Ciofi Degli; El Hachem, Maya; Oranje, Arnold P; Rubin, Agneta Troilius; Weibel, Lisa; Léauté-Labrèze, Christine (2015). Treatment of infantile haemangiomas: recommendations of a European expert group. European Journal of Pediatrics, 174(7):855-865.

Abstract

UNLABELLED With a prevalence of 2.6-4.5 %, infantile haemangiomas (IH) represent the most common tumour of infancy. While the majority of IH does not require therapy and regresses spontaneously, about 10 % of IH exhibit complications such as obstruction, ulceration or disfigurement. With the advent of oral propranolol, many conventional treatment options have become obsolete. This paper summarizes current recommendations for management of complicated IH. These recommendations have been written by an expert group after a consensus process including bibliographic review, several drafts of synthesis, meetings with quantitative voting system and redaction of an approved final manuscript. CONCLUSION Oral propranolol is the first-line agent for the treatment of complicated IH. WHAT IS KNOWN • Infantile haemangiomas (IH) are the most common tumours of infancy. Within a very short period after its discovery and long before the publication of randomized controlled trials, propranolol has become the number one agent for the treatment of complicated IH. What is New: • We report IH treatment recommendations of an international, interdisciplinary team of experts, based on an up-to-date review of the literature.

Abstract

UNLABELLED With a prevalence of 2.6-4.5 %, infantile haemangiomas (IH) represent the most common tumour of infancy. While the majority of IH does not require therapy and regresses spontaneously, about 10 % of IH exhibit complications such as obstruction, ulceration or disfigurement. With the advent of oral propranolol, many conventional treatment options have become obsolete. This paper summarizes current recommendations for management of complicated IH. These recommendations have been written by an expert group after a consensus process including bibliographic review, several drafts of synthesis, meetings with quantitative voting system and redaction of an approved final manuscript. CONCLUSION Oral propranolol is the first-line agent for the treatment of complicated IH. WHAT IS KNOWN • Infantile haemangiomas (IH) are the most common tumours of infancy. Within a very short period after its discovery and long before the publication of randomized controlled trials, propranolol has become the number one agent for the treatment of complicated IH. What is New: • We report IH treatment recommendations of an international, interdisciplinary team of experts, based on an up-to-date review of the literature.

Statistics

Citations

19 citations in Web of Science®
18 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Children's Hospital Zurich > Clinic for Surgery
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:July 2015
Deposited On:22 Jan 2016 08:26
Last Modified:05 Apr 2016 19:59
Publisher:Springer
ISSN:0340-6199
Publisher DOI:https://doi.org/10.1007/s00431-015-2570-0
PubMed ID:26021855

Download

Full text not available from this repository.
View at publisher